Omalizumab facilitates rapid oral desensitization for peanut allergy

@article{MacGinnitie2017OmalizumabFR,
  title={Omalizumab facilitates rapid oral desensitization for peanut allergy},
  author={Andrew J. MacGinnitie and Rima Rachid and Hana Gragg and Sara V. Little and Paul R Lakin and Antonella Cianferoni and Jennifer Heimall and Melanie M. Makhija and Rachel Glick Robison and Sharon Chinthrajah and John J. Lee and Jennifer S LeBovidge and Tina LR Dominguez and C. Brooks Rooney and Megan Ott Lewis and J. Koss and Elizabeth Burke-Roberts and Kimberly Chin and Tanya Logvinenko and Jacqueline A. Pongracic and Dale T. Umetsu and Jonathan M. Spergel and Kari Christine Nadeau and Lynda C. Schneider},
  journal={The Journal of Allergy and Clinical Immunology},
  year={2017},
  volume={139},
  pages={873–881.e8}
}

Figures and Tables from this paper

Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by Omalizumab.
Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab.
Peanut Immunotherapy: Practical Applications
TLDR
Data focuses on the data for efficacy, safety, and tolerability of OIT, SLIT, and EPIT with the aim of presenting information that will assist allergy practitioners in choosing an immunotherapy modality when indicated.
Oral immunotherapy for peanut allergy: The con argument
Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy
TLDR
OIT has been very well studied and has been found to be more efficacious than SLIT with an acceptable safety profile, however, SLIT is associated with fewer side effects.
Comparison of sublingual immunotherapy and oral immunotherapy in peanut allergy
TLDR
OIT has been very well studied and has been found to be more efficacious than SLIT with an acceptable safety profile, however, SLIT is associated with fewer side effects.
Peanut Oral Immunotherapy: a Current Perspective
TLDR
The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations.
Immunotherapy for Food Allergy: Are We There Yet?
Current developments in the treatment of peanut allergy
TLDR
Whether and which therapies for the treatment of peanut allergy will be available on the market in the future is not only relevant in terms of clinical effectiveness in the sense of a long-term stable increase in the threshold level, but also in termsof the tolerability in everyday life of affected patients.
Emerging Therapies for Peanut Allergy
TLDR
Oral, epicutaneous, and sublingual immunotherapies have completed clinical trials with promising efficacy and adjuvant combinations with either probiotics or anti-IgE receptor antagonists have shown an improved efficacy and safety profile compared to oral immunotherapy alone.
...
...

References

SHOWING 1-10 OF 51 REFERENCES
Oral peanut immunotherapy in children with peanut anaphylaxis.
Modified peanut oral immunotherapy protocol safely and effectively induces desensitization.
Sublingual versus oral immunotherapy for peanut-allergic children: a retrospective comparison.
Clinical efficacy and immune regulation with peanut oral immunotherapy.
Egg oral immunotherapy in nonanaphylactic children with egg allergy.
Effect of anti-IgE therapy in patients with peanut allergy.
TLDR
A 450-mg dose of TNX-901 significantly and substantially increased the threshold of sensitivity to peanut on oral food challenge from a level equal to approximately half a peanut to one equal to almost nine peanuts, an effect that should translate into protection against most unintended ingestions of peanuts.
...
...